Exact Sciences (NASDAQ:EXAS) Stock Rating Lowered by Baird R W

Exact Sciences (NASDAQ:EXAS) was downgraded by stock analysts at Baird R W from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Several other research analysts have also commented on the stock. Evercore ISI upped their price objective on shares of Exact Sciences from $64.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. TD Cowen increased their price target on shares of Exact Sciences from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Craig Hallum lowered shares of Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price objective for the company. in a report on Friday. BTIG Research cut Exact Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday. Finally, Wells Fargo & Company reissued an “equal weight” rating and issued a $105.00 target price (up previously from $85.00) on shares of Exact Sciences in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $79.38.

Exact Sciences Trading Up 0.2%

NASDAQ EXAS traded up $0.23 on Thursday, hitting $100.90. The company’s stock had a trading volume of 19,177,434 shares, compared to its average volume of 3,186,310. The firm has a market cap of $19.12 billion, a P/E ratio of -18.58, a PEG ratio of 5.56 and a beta of 1.34. Exact Sciences has a 52-week low of $38.81 and a 52-week high of $101.87. The company’s 50-day simple moving average is $62.85 and its 200 day simple moving average is $55.44. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.11. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The firm had revenue of $850.74 million for the quarter, compared to analysts’ expectations of $810.42 million. During the same period in the previous year, the firm earned ($0.21) earnings per share. The business’s revenue was up 20.0% compared to the same quarter last year. Exact Sciences has set its FY 2025 guidance at EPS. Research analysts predict that Exact Sciences will post -0.58 EPS for the current fiscal year.

Insider Activity

In related news, EVP Jacob A. Orville sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $75.00, for a total transaction of $375,000.00. Following the completion of the transaction, the executive vice president owned 23,237 shares of the company’s stock, valued at $1,742,775. This trade represents a 17.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the sale, the director directly owned 57,962 shares in the company, valued at $3,477,720. This trade represents a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 9,858 shares of company stock worth $695,289. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Exact Sciences

Hedge funds have recently bought and sold shares of the company. Westside Investment Management Inc. grew its position in Exact Sciences by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 271 shares during the last quarter. True Wealth Design LLC lifted its stake in shares of Exact Sciences by 951.8% in the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after buying an additional 533 shares in the last quarter. Country Trust Bank purchased a new stake in shares of Exact Sciences during the second quarter valued at approximately $32,000. Bessemer Group Inc. increased its position in shares of Exact Sciences by 1,980.6% during the second quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 614 shares in the last quarter. Finally, National Pension Service increased its position in shares of Exact Sciences by 75.1% during the first quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 292 shares in the last quarter. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.